DRKS00010992
Completed
Not Applicable
Prospective Evaluation of Circulating Tumour DNA (ctDNA) as Molecular Monitoring Tool and Prognostic Biomarker in Resectable Pancreatic Adenocarcinomas - ctDNA in resektablen Pankreaskarzinomen
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- C25
- Sponsor
- niversitätsklinikum Freiburg
- Enrollment
- 25
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Key inclusion criteria are resectable pancreatic adenocarcinoma and curatively intended, macroscopically complete (R0/R1\) resection.
Exclusion Criteria
- •Key exclusion criteria are Stage IV metastatic disease diagnosed prior to or during surgery and Non\-resectable tumour or macroscopically incomplete (R2\) resection. Histology other than primary adenocarcinoma is also not included. Other key exclusion criteria are malignancies diagnosed within the previous five years of diagnosis (except non\-melanoma skin cancer and carcinoma in situ of the cervix uteri).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Circulating tumor DNA (ctDNA) analyses as a predictive marker for cancer treatment in solid tumorsKCT0008188Chonnam National University Hospital Hwasun Hospital100
Active, not recruiting
Not Applicable
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell LymphomasPeripheral T Cell LymphomaNCT06089941Centre Henri Becquerel45
Recruiting
Not Applicable
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian CancerOvarian CancerNCT05446545Fudan University139
Active, not recruiting
Phase 4
CUARTET StudyMetastatic Castration-sensitive Prostate CancerJPRN-jRCTs071200040emura Hirotsugu100
Unknown
Not Applicable
The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal CancerColorectal CancerctDNASurveillanceNCT03416478Sixth Affiliated Hospital, Sun Yat-sen University50